ARVINAS INC
ARVNNASDAQTrading Snapshot
- Day Range
- $8.75 – $8.90
- 52-Week Range
- $6.44 – $14.51
- Volume
- $2.77B
- Avg Volume
- $2.69B
- Shares Outstanding
- 64.5M
- Next Earnings
- Oct 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $263M
- Last Q Revenue
- $250M
- P/E Ratio
- 47.3
- P/S Ratio
- 1.8x
- EPS (TTM)
- $0.14
- Dividend Yield
- 0.00%
Why Investors Own ARVN
- ✓High-growth profile — revenue up +26.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ARVINAS INC
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Evercore ISI Group Maintains Outperform on Arvinas, Lowers Price Target to $14
Evercore ISI Group analyst Jonathan Miller maintains Arvinas (NASDAQ:ARVN) with a Outperform and lowers the price target from $19 to $14.
Citigroup Maintains Buy on Arvinas, Lowers Price Target to $21
Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $24 to $21.
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market. Read why RIGL stock is a Buy.
Wells Fargo Downgrades Arvinas to Equal-Weight, Lowers Price Target to $11
Wells Fargo analyst Derek Archila downgrades Arvinas (NASDAQ:ARVN) from Overweight to Equal-Weight and lowers the price target from $15 to $11.
Wedbush Maintains Neutral on Arvinas, Raises Price Target to $12
Wedbush analyst Robert Driscoll maintains Arvinas (NASDAQ:ARVN) with a Neutral and raises the price target from $11 to $12.
BTIG Reiterates Buy on Arvinas, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Arvinas (NASDAQ:ARVN) with a Buy and maintains $18 price target.